MoneyWorks4Me

Clarification sought from Sanofi India

30 Oct 2015 Evaluate

The Exchange has sought clarification from Sanofi India with reference to news reported on CNBC TV18 on October 29, 2015-‘Setback For Glenmark: Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule.’

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..